Health Condition 1: null- COUGH DYSPNEA WHEEZE
Conditions
Interventions
Intervention1: VASADI KASHAYA: 50ML BD 30DAYS
Control Intervention1: NAYOPAYA KASHAYA: 50ML BD 30DAYS
Sponsors
Dr Pritali Shetye
Eligibility
Inclusion criteria
Inclusion criteria: 1 Patients of either sex with age between 18 to 60 years. 2 Newly diagnosed and patients with stable Bronchial Asthma (clinical features of Tamaka Å?vÄ?sa) (as per GINA Guideline) for at least 6 weeks prior to study entry. 3 Subjects with intermittent & mild persistent controlled bronchial asthma. 4 FEV1 of 5 Patients willing to participate and written consent.
Exclusion criteria
Exclusion criteria: 1 Patients with Status asthmaticus 2 Patients with evidence of malignancy. 3 Patients with uncontrolled Diabetes Mellitus of HbA1c >7.5%. 4 Patients with unstable cardiovascular disease. 5 Patients suffering from other major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Tuberculosis, Psycho-Neuro-Endocrinal disorders, etc.) 6 Patients with concurrent serious hepatic disorder or renal disorders. 7 Pulmonary disease other than bronchial asthma. 8 Drug abusers. 9 H/o hypersensitivity to the trial drug or any of its ingredients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| trail group has significant effect on asthmaTimepoint: spirometric analysis will be carried on 0th day and 31st day CBC abd AEC will be done on 0th and 31st day symptoms assessment will be done on 7th, 14th, 21st and 31st day | — |
Secondary
| Measure | Time frame |
|---|---|
| NONETimepoint: NONE | — |
Countries
India
Contacts
Public ContactDRPRITALI KISHOR SHETYE
KLEUS SHRI BMK AYURVEDIC MAHAVIDYALAYA PG AND RESEARCH CENTRE SHAHPUR BELAGAVI
Outcome results
None listed